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ABSTRACT
The Notch signaling pathway is conserved from Droso-
phila to mammals and is critically involved in develop-
mental processes. In the immune system, it has been
established that Notch signaling regulates multiple
steps of T and B cell development in both central and
peripheral lymphoid organs. Relative to the well docu-
mented role of Notch signaling in lymphocyte develop-
ment, less is known about its role in regulating myeloid
lineage development and function, especially in the
context of acute and chronic inﬂammation. In this review
article, we will describe the evidence accumulated dur-
ing the recent years to support a key regulatory role of
the Notch pathway in innate immune and inﬂammatory
responses and discuss the potential implications of
such regulation for pathogenesis and therapy of
inﬂammatory disorders.
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macrophages, Notch signaling, RBP-J
INTRODUCTION OF THE NOTCH SIGNALING
PATHWAY
The evolutionary conserved Notch signaling pathway regu-
lates cell proliferation, apoptosis and cell fate decisions
during development and adult tissue homeostasis (Radtke
et al., 2010). In mammalian cells there are four Notch
receptors (Notch 1–4), that are large single-pass type I
transmembrane proteins involved in transducing speciﬁc
extracellular signals to the nucleus in response to ligand
binding. Following translation from a single mRNA transcript,
the Notch protein is proteolytically cleaved at site S1 by a
furin-like convertase in the Golgi complex and subsequently
reassembled into the functional heterodimeric receptor pre-
sent at the cell surface. The resulting Notch molecule con-
sists of the extracellular domain non-covalently associated
with the transmembrane and intracellular domains. The
extracelluar domain of all Notch proteins contains 29–36
tandem epidermal growth factor (EGF)-like repeats that
mediate ligand interaction, followed by 3 cysteine-rich LIN12
repeats that prevent ligand-independent activation. A
hydrophobic stretch of amino acids mediates the
heterodimerization between the extracellular, and the trans-
membrane plus intracellular subunits of the Notch receptor.
The intracellular region harbors multiple conserved func-
tional elements including nuclear localization signals, a RAM
(RBP-J-association module) domain, ankyrin repeats
involved in protein interactions, a trans-activation domain
and a C-terminal PEST (praline/glutamic acid/serine/thre-
onine) domain that regulates protein stability (Kopan and
Ilagan, 2009).
Canonical Notch signaling is initiated by the binding of the
extracellular domain of the Notch receptor to Notch ligands
on neighboring cells. In mammals there are ﬁve Notch
ligands (Jagged1, Jagged2, Delta-like 1 (DLL1), DLL3, and
DLL4). Cell type-speciﬁc and spatial expression of ligands
and/or receptors can regulate Notch signaling to a certain
cell context or population (Radtke et al., 2010). Additionally,
different ligands and receptors are subject to regulation by
other cell signaling pathways triggered by a variety of stimuli
(Kopan and Ilagan, 2009). Ligation of Notch receptors by
their ligands leads to a sequence of proteolytic events.
Firstly, a disintegrin and metalloprotease (ADAM) proteases
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cleave the receptor at site S2 to release the extracellular
domain, which is subsequently endocytosed by the ligand-
expressing cell. Following shedding of the extracellular
domain, a second cleavage event occurs at site S3 within
the transmembrane domain mediated by the multicompo-
nent protease γ-secretase, resulting in the release of the
Notch intracellular domain (NICD). NICD is subsequently
translocated to the nucleus where it interacts via its RAM
domain with the DNA-binding protein recombinant recogni-
tion sequence binding protein at the Jκ site (RBP-J, also
named CSL or CBF1). In the absence of NICD, RBP-J is
bound to speciﬁc DNA binding sites ((C/T)GTGGAA) and is
thought to act as a transcriptional repressor due to its ability
to bind transcriptional corepressors (NCoRs) and histone
deacetylases (HDACs). Binding of NICD displaces co-re-
pressor complexes and recruits co-activators including
mastermind proteins (MAML1–3), which in turn recruit tran-
scription activation complex in order to induce transcription
of Notch target genes (Kopan and Ilagan 2009). Thus RBP-J
serves as the nuclear mediator of canonical Notch signaling.
Following transcriptional regulation of target genes, NICD is
degraded in the nucleus by the ubiquitin-proteasome sys-
tem. In mammals, the best-described canonical Notch target
genes are members of the basic-helix-loop-helix transcrip-
tion factors belonging to the hairy and enhancer of split (Hes)
and hairy and enhancer of split with YRPW motif (Hey)
families, including Hes1, Hes5, and Hes7 as well as Hey1,
Hey2, and HeyL (Iso et al., 2003). Additional direct Notch
target genes include Deltex1 (Izon et al., 2002), Il2ra, Gata3,
and Myc (Borggrefe and Oswald, 2009). Recent studies
using global expression analysis and chromatin immuno-
precipitation deep-sequencing (ChIP-seq) have revealed
genome-wide Notch-RBP-J targets in various systems
including hematopoiesis (Hamidi et al., 2011), Epstein-Barr
virus infection (Zhao et al., 2011), T-lymhoblastic
leukemia/lymphoma (Palomero et al., 2006; Wang et al.,
2011), and macrophages (Xu et al., 2015).
One of the most established functions for Notch signaling
in the immune system is the differentiation of lymphoid Tand
B cell lineages (Tanigaki and Honjo, 2007), as well as T cell
activation (Eagar et al., 2004), regulatory T cell function
(Ostroukhova et al., 2006) and T helper cell differentiation
(Amsen et al., 2007; Amsen et al., 2004; Fang et al., 2007;
Maillard et al., 2005; Osborne and Minter, 2007; Skokos and
Nussenzweig, 2007). These lymphoid-related functions
associated with Notch signaling have recently been
reviewed (Radtke et al., 2010; Yuan et al., 2010; Yashiro-
Ohtani et al., 2010). Less well characterized, however, is the
role of Notch signaling in innate immune cell development
and function. This review aims to discuss recent ﬁndings
elucidating a key role for Notch signaling in differentiation,
activation and function of the myeloid cells involved in innate
immunity and inﬂammation. First, we will present evidence
supporting the notion that active Notch signaling is associ-
ated with a variety of inﬂammatory conditions. Next, we will
summarize the current knowledge on regulation of myeloid
cell differentiation and function by the Notch pathway. Finally,
we discuss the involvement of the Notch pathway in human
inﬂammatory and autoimmune diseases and the potential of
targeting Notch signaling as a new approach to modulating
inﬂammation.
ACTIVE NOTCH SIGNALING UNDER
INFLAMMATORY CONDITIONS
Recently, evidence has been mounting that Notch signaling
is associated with innate immunity and inﬂammation. To
date, active Notch signaling has been observed under a
variety of inﬂammatory conditions including rheumatoid
arthritis (RA) (Nakazawa et al., 2001a; Ando et al., 2003;
Jiao et al., 2010; Yabe et al., 2005; Ishii et al., 2001; Naka-
zawa et al., 2001b; Park et al., 2015), systemic lupus ery-
thematosus (SLE) (Murea et al., 2010; Zhang et al., 2010),
atherosclerosis (Fung et al., 2007; Aoyama et al., 2009),
systemic sclerosis (Dees et al., 2011), primary biliary cir-
rhosis (Shackel et al., 2001), preterm labor (Jaiswal et al.,
2015), as well as during bacterial and viral infections (Nar-
ayana and Balaji 2008; Ito et al., 2009; Ito et al., 2011). Given
the recent identiﬁcation of RBPJ, a gene encoding a key
nuclear mediator of the canonical Notch pathway, as one of
the new RA risk loci (Stahl et al., 2010), association of active
Notch signaling with RA is of particular interest. Expression
of Notch receptors and ligands were detected in the RA
synovial tissues (Nakazawa et al., 2001; Ando et al., 2003;
Yabe et al., 2005; Ishii et al., 2001) and aberrant activation of
Notch1 was observed in primary synoviocyte cultures from
RA patients (Nakazawa et al., 2001). Thus, there is com-
pelling evidence suggesting that the Notch pathway is acti-
vated in RA and may modulate disease activities.
Although association of active Notch signaling with
inﬂammatory conditions is supported by a growing body of
literature, the mechanisms by which infection and inﬂam-
mation modulate Notch signaling remain poorly understood.
Under an inﬂammatory environment, it is conceivable that
Notch signaling in myeloid cells could be promoted by stimuli
that are broadly categorized into two groups: exogenous
agents such as pathogens and/or endogenous factors such
as cytokines. In the following sections, we will discuss the
current knowledge on regulation of Notch signaling by TLR
ligands and by inﬂammatory cytokines respectively.
Regulation of Notch signaling by TLRs
Macrophages and dendritic cells (DCs) express a variety of
pattern recognition receptors (PRRs) including toll-like
receptors (TLRs) that enable them to rapidly respond to
pathogen infections and to coordinate innate and adaptive
immune responses. Meanwhile, macrophages and DCs also
constitutively express Notch ligands and receptors on their
cell surface and thus have the capacity to both induce and
respond to Notch signals. One mechanism by which TLRs
modulate Notch signaling is by inducing Notch receptor and
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ligand expression. There is amble evidence that activation of
macrophages and DCs with TLR ligands leads to induction
of Notch receptors and ligands including Jagged1, DLL1,
and DLL4 (Amsen et al., 2004; Fung et al., 2007; Foldi et al.,
2010; Monsalve et al., 2006; Monsalve et al., 2009; Palaga
et al., 2008; Zhang et al., 2012). Induction of Notch receptor
and ligands by puriﬁed or synthetic TLR ligands is further
conﬁrmed by the experiments using bacterial and viral
pathogens such as Mycobacterium bovis Bacille Calmette-
Guerin (BCG) and inﬂuenza H1N1 virus (Narayana and
Balaji, 2008; Ito et al., 2009; Ito et al., 2011). Via augmenting
expression of Notch receptors and/or ligands, TLR signaling
indirectly promotes Notch pathway activation and expression
of canonical Notch target genes in a manner that is predicted
to be dependent on de novo protein synthesis. In addition to
the above described indirect activation, we have shown that
in human primary macrophages, activation of Notch target
genes such as Hes1 and Hey1 can be directly induced by
TLR stimulation (Hu et al., 2008). The current observations
regarding direct activation of Notch target genes by TLRs
support a binary model where signal 1 is provided by tonic
Notch signaling and signal 2 is provided by acute TLR sig-
naling (Fig. 1). This binary model is consistent with the fol-
lowing results: (1) As a result of constitutive expression of
Notch receptors and ligands, resting macrophages display
tonic Notch signaling evidenced by basal levels of NICD. (2)
Once triggered by TLR stimulation, activation of Notch target
gene expression occurs rapidly in the absence of new
protein synthesis, circumventing the requirement for activa-
tion secondary to receptor or ligand induction. (3) Signal 1 or
signal 2 alone is necessary but not sufﬁcient for full ﬂedged
Notch target gene expression in macrophages. Cooperation
of both signaling pathways is required for optimal activation.
In summary, recent work from a number of laboratories
suggests that activation of Notch target genes is a common
feature of TLR responses and can occur via two non-mutu-
ally exclusive mechanisms, direct activation by acute TLR
signaling and indirect activation secondary to Notch receptor
and ligand induction. However, a key question that remains
unanswered is the identity of the signal that couples acute
TLR signaling to Notch pathway activation. Detailed bio-
chemical analysis of Notch pathway components upon TLR
stimulation may help solve this issue and yield further insight
into the mechanisms of Notch-TLR crosstalk. Another
question is the source of so-called “tonic” Notch signaling in
myeloid cells. The Notch pathway can be activated in mac-
rophages and DCs in vivo by Notch ligands that are
expressed by macrophages and DCs themselves, and also
by Notch ligands expressed on stromal and epithelial cells in
the marginal zone of the spleen, thymic epithelium and bone
marrow stromal cells, or on stromal cells at inﬂammatory
sites such as rheumatoid arthritis synovium (Tanigaki and
Honjo, 2007; Caton et al., 2007). Future studies utilizing the
Notch activity reporter system in vivo might be useful in























Figure 1. A model for activation of Notch target gene expression in human macrophages. Both signal 1 and signal 2 are
required to achieve full-ﬂedged induction of Notch target genes by stimuli such as TLR ligands. Signal 1 is provided by constitutive
tonic Notch signaling in macrophages presumably as a result of macrophage-macrophage or macrophage-stromal cell interaction.
Signal 2 is provided by TLR stimulation in the form of p38-mediated phosphorylation of histones at the Notch target gene loci.
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Regulation of Notch signaling by inﬂammatory
cytokines
In the section above, we have discussed regulation of the
Notch pathway by agents that are foreign to our bodies such
as TLR ligands. In this section, we will extend the discussion
to regulation of Notch signaling by endogenous factors that
are highly involved in immune regulation. Inﬂammatory
cytokines such as TNF and interlukin-1β (IL-1β) are abun-
dantly present during the course of innate immune and
inﬂammatory responses and are essential for host defense
against a variety of pathogens. However, under conditions of
uncontrolled inﬂammation and in autoimmune diseases,
dysregulated production and/or action of inﬂammatory
cytokines can be detrimental and pathogenic. For example, it
is well established that TNF plays a key role in RA patho-
genesis and is a validated drug target of RA. Interestingly, in
RA synovial ﬁbroblasts, TNF induces expression of Notch1,
Notch4, and Jagged2 as well as NICD nuclear translocation,
a hallmark of Notch pathway activation (Ando et al., 2003).
Moreover, in osteoclast precursors, Notch-RBP-J signaling
is activated by TNF and in turn inhibits osteoclastogenesis
and attenuates TNF-mediated inﬂammatory bone resorption
in a feedback manner (Zhao et al., 2012). Another example
of TNF-induced Notch activation is observed in a mouse
pancreatic cancer model where TNF promotes expression of
Notch target genes Hes1 and Hey1 (Maniati et al., 2011).
Thus, TNF appears to function as an activator of Notch
signaling in several cell types. IL-1β is another important pro-
inﬂammatory cytokine. It is reported that IL-1β induces Notch
target gene Hes1 expression in chondrocytes via Notch1
activation, suggesting that similar to TNF, IL-1β also has the
potential to serve as Notch activator (Ottaviani et al., 2010).
In addition to the prototypical pro-inﬂammatory cytokines
such as TNF and IL-1β, TGFβ has also been shown to
directly induce Hes1 expression in several cell types
(Ostroukhova et al., 2006), expanding the panel of Notch-
activating cytokines to include the anti-inﬂamma-
tory/pleiotropic family. While many cytokines positively reg-
ulate Notch signaling and its target gene expression,
interferon-γ (IFNγ) functions as a negative regulator of Notch
pathway activation. In human primary macrophage, IFNγ
drastically suppresses induction of canonical Notch target
genes by TLR ligands and by Notch ligands (Hu et al., 2008).
The precise mechanisms by which IFNγ antagonizes Notch
signaling remain poorly deﬁned and represents an interest-
ing topic for future investigation.
Molecular mechanisms of Notch activation
by inﬂammatory stimuli
Notch target gene expression can be activated in myeloid
cells by a wide array of inﬂammatory stimuli including TLR
ligands and cytokines. However, the molecular mechanisms
of such activation are ill deﬁned. One attractive candidate
pathway that could potentially mediate activation of Notch
target genes in myeloid cells is NF-κB signaling that is
activated by both TLR ligands and inﬂammatory cytokines
and has been shown to interact with the Notch pathway in
many systems such as cancer (Espinosa et al., 2010).
Indeed, TLR and TNF-induced Notch target gene expression
is often dependent on inhibitor of NF-κB kinases (IKKs) (Hu
et al., 2008; Maniati et al., 2011), kinases required for NF-κB
activation by inﬂammatory stimuli. Another group of signaling
molecules implicated in mediating Notch pathway activation
are mitogen-activated protein kinases (MAPKs) (Hu et al.,
2008; Zeng et al., 2005), a family of serine/threonine protein
kinases many of which are key regulators of inﬂammation. At
least three distinct yet complementary mechanisms have
been described to explain NF-κB-mediated activation of
canonical Notch target genes: (1) Transcription factor
cooperation. NICD has been shown to directly interact with
NF-κB subunits and promotes transcription (Osipo et al.,
2008). (2) Release of inhibitory molecules. For example, in
resting cells inhibitor of NF-κB (IκB), which typically
sequesters NF-κB in cytoplasm, was found to be present at
the promoter regions of Hes1. Interestingly, TNF-induced
Hes1 expression was thought to be associated with dis-
missal of IκBα from the Hes1 promoter (Aguilera et al.,
2004). (3) Chromatin modiﬁcation. TNF and TLR ligand-in-
duced Hes1 gene transcription has been associated with
upregulation of positive histone marks such as serine 10
phosphorylation and K14 acetylation of histone H3 at the
Hes1 promoter (Hu et al., 2008; Maniati et al., 2011; Aguilera
et al., 2004). Both IKKs and MAPKs have been implicated in
mediating inﬂammatory signaling-induced chromatin modiﬁ-
cations at the Notch target gene loci (Hu et al., 2008; Zeng
et al., 2005; Aguilera et al., 2004). Taken together, NF-κB
and MAPK signaling appears to play a critical role in medi-
ating Notch target gene activation by inﬂammatory stimuli.
REGULATION OF MYELOID DIFFERENTIATION BY
NOTCH SIGNALING
The notion that inﬂammatory signals regulate Notch signal-
ing and activate Notch target gene expression in myeloid
cells has been increasingly appreciated as discussed above
(Fig. 2). One obvious question is what are the roles of the
Notch pathways in myeloid cell differentiation and function.
In the following two sections, we will ﬁrst discuss regulation
of myeloid differentiation by Notch signaling under homeo-
static conditions, and then the role of the Notch pathway in
myeloid activation under immune and inﬂammatory
conditions.
Notch signaling and hematopoietic stem cells
Hematopoiesis is the developmental process, whereby
pluripotent hematopoietic stem cells (HSCs) give rise to
committed progeny that undergo proliferation and differenti-
ation in response to both positive and negative soluble and
cell-bound factors and cytokines, resulting in the continuous
REVIEW Yingli Shang et al.









production of mature blood cells of various lineages. In the
developing immune system, the Notch signaling pathway
regulates interactions between HSCs, which express all four
Notch receptors, and bone marrow stromal cells, which
express various Notch ligands (Bigas et al., 2010). In this
section, we will discuss recent progress in understanding the
role of the Notch pathway in development and differentiation
of myeloid cells. Although Notch signaling is thought to play
a key role in myeloid cell differentiation from HSCs, there are
discrepancies as to the mechanisms involved. One body of
evidence demonstrates a role for Notch in the maintenance
of progenitor cells and block of terminal differentiation of
myeloid cells. In support of this hypothesis, retroviral trans-
duction of the activated intracellular domain of Notch1
(NICD1) in 32D myeloid progenitor cells inhibited differenti-
ation of mature granulocytes in response to granulocyte
colony-stimulating factor (G-CSF), but not granulocyte
macrophage colony stimulating factor (GM-CSF), without
affecting proliferation of undifferentiated cells (Milner et al.,
1996; Bigas et al., 1998). NICD2 inhibited differentiation of
32D cells in response to GM-CSF but not G-CSF (Bigas
et al., 1998). These ﬁndings suggested that although both
Notch1 and Notch2 inhibited myeloid differentiation, they
may have distinct functions in HSCs depending on the
speciﬁc differentiation signal involved. The Notch RAM
domain, which contains the RBP-J binding region, was
subsequently shown to be required for these Notch-
mediated functions (Tan-Pertel et al., 2000), implying that
Notch signals through the canonical RBP-J-dependent
pathway to inhibit terminal differentiation and enhance sur-
vival of 32D myeloblast cells. Over-expression of the
downstream RBP-J target Hes1 resulted in a similar phe-
notype (Tan-Pertel et al., 2000; Kumano et al., 2001). In
addition, NICD1 or Hes1 expression blocked erythroid dif-
ferentiation (Kumano et al., 2001; Lam et al., 2000) and
Notch1 inhibition using a loss-of function approach resulted
in spontaneous erythroid maturation (Lam et al., 2000).
Promotion of HSC self-renewal and differentiation inhibition
was also observed in response to various Notch ligands
(Varnum-Finney et al., 1998; Carlesso et al., 1999; Varnum-
Finney et al., 2003; Han et al., 2000).
On the other hand, Notch has been shown to be required
for differentiation of mature myeloid cells. For example,
Schroeder et al. (2000) demonstrated that conditional
expression of NICD1 in 32D cells enhanced granulocyte
differentiation and decreased self-renewal. Experiments
using NICD1 deletion mutants indicated a role for the RAM
domain in this process, and either Jagged1 stimulation or
expression of a transcriptionally active form of RBP-J in 32D
cells also promoted myeloid differentiation (Schroeder and
Just, 2000).
Recently Klinakis et al. (2011) outlined a role for Notch
signaling during early HSC differentiation in vivo. Inactivation






















Figure 2. Regulation of myeloid cell development and differentiation by Notch signaling. Notch signaling critically controls
multiple steps of myeloid cell development and differentiation program including early myelopoiesis, development of certain DC
population, osteoclast differentiation, and inﬂammatory macrophage polarization. Abbreviations: HSC, hematopoietic stem cell; GMP,
granulocyte-macrophage progenitor; MDP, macrophage-dendritic cell progenitor; CDP, common dendritic cell precursor; OCP,
osteoclast precursor; pDC, plasmacytoid dendritic cells.
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member Nicastrin in mouse HSCs resulted in an aberrant
accumulation of granulocyte/monocyte progenitors in
peripheral blood, spleen and liver, diagnostic of the induction
of chronic myelomonocytic leukemia (CMML)-like disease.
Gene expression analysis revealed that Notch signaling
regulates a myelomonocytic-speciﬁc gene signature through
the suppression of gene transcription by Hes1. Further,
somatic mutations were identiﬁed in multiple Notch pathway
genes, including those that encode Nicastrin, MAML1 and
Notch2, in samples from CMML patients, demonstrating a
tumor-suppressive role for Notch signaling in addition to
involvement in early HSC differentiation (Klinakis et al.,
2011).
Notch signaling and dendritic cell differentiation
In recent years, there has been much interest in the role of
Notch signaling during the development of DCs (Cheng and
Gabrilovich, 2008), which represent the key professional
antigen presenting cells involved in the immune response to
pathogens, tumor cells, and self antigens. DCs sample the
environment in tissues and lymphoid organs and recognize
pathogen-associated molecular patterns (PAMPs) by means
of PRRs. Pathogen recognition and capture triggers a cas-
cade of signaling events that leads to DC maturation, which
involves outgrowth of dendrites, increased expression of
MHC class II and co-stimulatory molecules, secretion of
cytokines such as IL-12 and migration into T cell areas of
lymphoid organs to present peptide antigen to naïve T cells.
Thus, DCs are intimately involved in linking the innate and
adaptive arms of the immune system.
There are two major subclasses of DCs, including con-
ventional DCs (cDCs), which differentiate from myeloid
progenitors in the bone marrow and plasmacytoid DCs
(pDCs), which can arise from cells of both myeloid and
lymphoid origin and specialize in virus recognition and
secretion of type I interferon (IFN). cDCs are further classi-
ﬁed according to their surface expression of speciﬁc myeloid
markers. The more abundant CD8−CD11b+ DCs reside in
the marginal zone of the splenic lymphoid follicles, a struc-
ture that ﬁlters incoming blood, and preferentially present
exogenous antigens on MHC class II protein to CD4 helper T
cells. CD8+CD11b− DCs, on the other hand, are thought to
mainly reside in T cell zones of the spleen, and present
antigen via MHC class I to cytotoxic T cells (Sathe and Wu,
2011).
A potential role for Notch in the development of cDCs has
been suggested by various in vitro studies (Ohishi et al.,
2001; Weijzen et al., 2002; Cheng et al., 2003; Cheng et al.,
2007; Zhou et al., 2009; Sekine et al., 2009; Cheng et al.,
2001; Mizutani et al., 2000). Differentiation of mature DCs
expressing MHC class II molecules in response to GM-CSF
and IL-4 stimulation was decreased in HPCs from anti-sense
Notch1 transgenic mice compared to cells from control mice
(Cheng et al., 2001). Transduction of the anti-sense Notch1
HPCs with a constitutively active Notch1 almost completely
restored the differentiation ability (Cheng et al., 2001).
Studies from the same laboratory later strengthened these
observations by demonstrating that DC differentiation was
inhibited in embryonic stem cells and HSCs from Notch1-
deﬁcient mice (Cheng et al., 2003). Additionally, stimulation
of primary murine peripheral blood monocytes with immobi-
lized DLL1 inhibited macrophage development but permitted
differentiation into DCs (Ohishi et al., 2001) and DLL1 may
exert its effect on DC differentiation via activation of the Wnt
signaling pathway (Zhou et al., 2009). In addition to the role
of DLL1 in the development of differentiated DC populations,
other Notch ligands participate (Sekine et al., 2009) and it
has been demonstrated that Jagged1 induced DC differen-
tiation in human monocytes (Weijzen et al., 2002). Further
studies demonstrated that individual Notch ligands can dif-
ferentially regulate DC differentiation. DLL1-expressing
ﬁbroblasts co-cultured with HPCs induced DC differentiation,
whereas Jagged-1 expressing ﬁbroblasts inhibited DC dif-
ferentiation and promoted accumulation of immature myeloid
cells (Cheng et al., 2007). The distinct effects of the various
Notch ligands may reﬂect their physiological functions in the
body as there is differential expression of Notch ligands in
bone marrow and splenic stroma (Cheng and Gabrilovich,
2008).
In contrast to these ﬁndings, initial in vivo experiments
demonstrated that although conditional knockout of Notch1
blocked T cell development in mice, myeloid development
was not affected (Radtke et al., 1999; Radtke et al., 2000).
However, it is possible that normal DC development in the
absence of Notch1 is due to the potential redundancy of
individual Notch receptors. As deletion of RBP-J is thought to
recapitulate the phenotypes of individual receptor knockouts
and of dominant-negative inhibition of Notch signaling,
Caton et al. (2007) investigated the function of canonical
Notch-RBP-J signaling using mice with a speciﬁc deletion of
RBP-J in the DC compartment. They demonstrated that
Notch signaling was essential for DC homeostasis in the
spleen, in particular for survival and persistence of splenic
CD8−CD11b+ DCs in the marginal zone, as evidenced by
reduced cell survival and increased turnover in RBP-J-deﬁ-
cient mice. Other subsets of splenic DCs and DCs in the
lymph nodes and tissues were not affected by RBP-J dele-
tion and the selective requirement for Notch signaling in the
CD8−CD11b+ DCs correlated with the speciﬁc and RBP-J-
dependent expression of the Notch target gene Dtx1 (Caton
et al., 2007). This group subsequently identiﬁed the Notch
receptor involved in this phenotype and has demonstrated a
key role for Notch2 (Lewis et al., 2011). Speciﬁc deletion of
Notch2 in the DC compartment resulted in decreased num-
bers of CD11b+ DCs. Within this cell subset, blockade of
Notch signaling ablated a distinct population characterized
by high expression of the adhesion molecule ESAM, which is
expressed on endothelium and regulates neutrophil
extravasation. In support of these ﬁndings, NICD over-ex-
pression increased ESAM expression on CD11b+ DCs.
Additionally Notch2 deletion led to the loss of CD11b+CD103
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DCs in the intestinal lamina propria (Lewis et al., 2011).
Consistent with the earlier ﬁndings using global Notch1
deletion (Radtke et al., 2000), speciﬁc deletion of Notch1 in
DC populations was found to be dispensable for splenic DC
development. Taken together, these ﬁndings imply a role for
canonical Notch-RBP-J signaling in the development of tis-
sue-speciﬁc DCs in the spleen and intestine and indicate
that Notch2 is the speciﬁc receptor involved in these
processes.
pDCs are phenotypically and functionally different from
cDCs. Both positive and negative effects of Notch signaling
on pDC development have been reported. In one study,
Notch signaling via DLL1 was shown to support pDC for-
mation from human HSCs (Olivier et al., 2006). A γ-secre-
tase inhibitor (GSI) blocked this effect (Olivier et al., 2006).
However, DLL1 blocked pDC development from early thymic
precursors (Dontje et al., 2006). Inactivation of Notch1 did
not affect the development of pDCs, suggesting that this
receptor is not essential for differentiation of this cell subtype
(Radtke et al., 2000; Lewis et al., 2011; Ferrero et al., 2002).
The reasons for the differences in the various reports
outlined above are unclear. Experimentally, different con-
structs and protein expression systems, mouse models and
Notch ligands (soluble or immobilized) were used. Moreover,
it is widely accepted that Notch signaling is highly cell con-
text speciﬁc and in the hematopoietic microenvironment, the
effects of Notch activation on HSCs are likely to be inﬂu-
enced by growth factors, cytokines and cross-talk with other
signaling pathways that tailor the developmental cell fate.
Physiological stimulation of Notch activity in vivo is likely to
be transient in nature. Additionally, although RBP-J plays a
key role in canonical Notch signaling, Notch can signal
independently of RBP-J and RBP-J can be activated by
alternative signaling pathways (Martinez Arias et al., 2002).
While the precise molecular mechanisms of Notch-mediated
regulation are far from fully understood, it is clear that Notch
signaling inﬂuences differentiation of speciﬁc myeloid sub-
sets in a cell- and ligand-speciﬁc context.
Notch signaling and osteoclastogenesis
Physiological bone development and remodeling represents
a balance between bone formation by osteoblasts and bone
resorption mediated by osteoclasts, which are multinucle-
ated cells derived from the monocyte-macrophage lineage.
Osteoclast differentiation is a multi-step process that culmi-
nates in expression of the osteoclast marker TRAP (tartrate-
resistant acid phosphatase), multinucleation and bone-re-
sorping activity. Osteoclastogenesis depends on differentia-
tion signals from stromal cells and synovial ﬁbroblasts, and is
physiologically triggered by RANKL (receptor activator of
NF-κB ligand) in the presence of M-CSF and other co-stim-
ulatory factors. Recruitment of these resorptive cytokines
can be physiologically restricted by osteoprotegerin (OPG,
also known as osteoclastogenesis inhibitory factor) (Zhao
and Ivashkiv, 2011). RANKL stimulation of osteoclast
precursors leads to the induction of cell signaling cascades
resulting in activation of the master transcriptional regulator
of osteoclastogenesis, NFATc1 (nuclear factor of activated T
cells, cytoplasmic 1). Numerous inﬂammatory molecules,
such as TNFα, IL-1β, IL-17, and TLR ligands, promote
osteoclastogenesis in synergy with RANKL to induce
pathological bone resorption in inﬂammatory settings. As
such, osteoclasts have been implicated in musculoskeletal
tissue damage and the pathogenesis of diseases charac-
terized by inﬂammatory osteolyis, including RA, psoriatic
arthritis, and peridontitis. In these disease settings, abnor-
mally enhanced osteoclast formation and activity causes
bone loss that results in pain, deformity, osteopenia, osteo-
porosis and even fracture. The extent of bone destruction in
inﬂammatory disease is determined by the balance between
positive and negative regulators of osteoclastogenic factors
(Zhao and Ivashkiv, 2011).
Notch signaling has been implicated in osteclastogenesis
during normal bone homeostasis and inﬂammation. Notch
receptors, ligands and target genes have been detected in
osteoclast precursors and differentiated osteoclasts
(Yamada et al., 2003; Bai et al., 2008; Fukushima et al.,
2008). A role for Notch in promoting osteoclast differentiation
has been described. Suppression of Notch signaling by GSI
treatment or shRNA for Notch2 inhibited RANKL-induced
osteoclast differentiation (Fukushima et al., 2008), whereas
activation of Notch signaling by stimulation with Jagged1 or
NICD2 over-expression increased NFATc1 promoter activity
and promoted osteoclastogenesis (Fukushima et al., 2008).
However, the remaining body of evidence investigating
Notch signaling during osteoclast development has indicated
a suppressive role for Notch. Firstly, Yamada et al.,
demonstrated that immobilized DLL1 inhibited osteoclast
differentiation from mouse bone marrow cells in response to
RANKL and M-CSF (Yamada et al., 2003). DLL1 also
decreased surface expression of the M-CSF receptor c-Fms
on the bone marrow cells. Stromal cells over-expressing
NICD1 reduced M-CSF production and enhanced RANKL
and OPG production, resulting in the decreased capability of
these cells to support osteoclastogeneis (Yamada et al.,
2003). Subsequently, genetic approaches indicated that
deletion of Notch1 or combined Notch1–3 enhanced osteo-
clastogenesis in response to M-CSF or RANKL, resulting in
increased resorptive activity (Bai et al., 2008). Osteoclast
precursors with inactivated Notch1–3 exhibited increased
expression of c-Fms. Overexpression of NICD1 or Jagged1
stimulation of wild type BMDMs blocked their differentiation
into osteoclasts in response to M-CSF and RANKL (Bai
et al., 2008).
Further studies have supported an inhibitory role for
Notch in the context of TNFα-induced osteoclastogenesis in
the inﬂammatory setting (Zhao et al., 2012). RBP-J was
shown to strongly repress TNF-induced osteoclastogenesis,
as myeloid speciﬁc deletion of RBP-J dramatically increased
osteoclastogenesis and resulted in severe bone destruction
in a TNF-induced inﬂammatory bone resorption model.
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Additionally, knockdown of RBP-J expression in human
osteoclast precursors by RNAi enhanced TNF-induced
osteoclast differentiation. By activating RBP-J using forced
expression of NICD1 in myeloid osteoclast precursors, TNF-
induced inﬂammatory bone resorption was dramatically
decreased. RBP-J was demonstrated to suppress induction
of NFATc1 by attenuating cFos activation and inhibiting
induction of Blimp1, thereby preventing the downregulation
of transcriptional repressors such as IRF8 that block osteo-
clast differentiation (Zhao et al., 2012). Such inhibitory
effects are possibly attributed to Notch-mediated crosstalk
with other pathways such as immunoreceptor tyrosine-
based activation motif-containing (ITAM-containing) recep-
tors and adaptors (Li et al., 2014) as well as TAK1 signaling
(Swarnkar et al., 2015). Thus, the majority of studies have
delineated a direct inhibitory role for Notch signaling in the
physiological context of osteoclastogenesis and inﬂamma-
tory bone resporption. In addition, Notch signaling may
indirectly regulate osteoclast differentiation in vivo by regu-
lating the differential expression of RANKL and OPG on
osteoblast lineage cells (Hilton et al., 2008; Engin et al.,
2008; Zanotti and Canalis, 2010).
REGULATION OF MYELOID ACTIVATION AND
FUNCTION BY NOTCH SIGNALING
Besides its role in myeloid cell differentiation, recently there
is increasing evidence supporting a role for Notch signaling
in regulating activation and function of terminally differenti-
ated myeloid cells. As regulation of acute activation by the
Notch pathway is still an emerging concept in the ﬁeld, there
are controversies regarding the exact roles and mechanisms
of action of this pathway. We will summarize the current
knowledge regarding regulation of activation and function of
myeloid cells by Notch signaling below.
Notch signaling in DC function
Accumulating evidence has indicated that Notch signaling
inﬂuences both functional DC maturation and DC-mediated
T cells responses. Notch receptors are expressed on T cells
and Notch ligands are expressed on DCs (Cheng and
Gabrilovich, 2008). As mentioned above, pathogen recog-
nition triggers DC activation and presentation of peptide
antigen to naïve T cells, thus expression of surface mole-
cules on DCs speciﬁes the T cell response. Th1 cells are
characterized by production of IFNγ and are mainly involved
in cellular immunity against intracellular pathogens. On the
other hand, Th2 cells play a role in immunity against extra-
cellular pathogens. Indeed, certain ﬁndings support a ligand-
speciﬁc role for DC-expressed Notch ligands in specifying
various T cell lineages (Amsen et al., 2004; Skokos and
Nussenzweig, 2007; Ito et al., 2009; Maekawa et al., 2003;
Hoyne et al., 2000; Schaller et al., 2007). Further, the ESAM
high DC population identiﬁed by Lewis et al., whose devel-
opment depended on canonical Notch2-RBP-J signaling,
was required for optimal Tcell priming (Lewis et al., 2011), as
evidence by decreased T cell proliferation in the spleens of
RBP-J-deﬁcient mice that speciﬁcally lacked the ESAM high
subset. Additionally, Notch2 provided a tissue-speciﬁc
developmental signal for the CD11b CD103 DC population in
the small intestine and colon, which supported optimal dif-
ferentiation of Th17 cells, a major effector CD4 population in
this tissue type (Lewis et al., 2011). Notch2 induction in
IL-19-mediated regulation of lung DC maturation has been
demonstrated and this could have potential implications for
antigen presenting cells involved in autoimmune disease, as
IL-19 has been reported to enhance chronic inﬂammation
associated with asthma, psoriasis and rheumatoid arthritis
(Hoffman et al., 2011). However, there are also reports
suggesting lack of a role of Notch signaling in specifying Th
cell fate especially Th1 versus Th2 differentiation (Ong et al.,
2008). The precise involvement of Notch in Th differentiation
remains to be sorted out possibly awaiting experiments uti-
lizing genetic fate mapping tools.
RBP-J has been shown to play a critical role in the mat-
uration of peptide or LPS-induced DCs (Weijzen et al., 2002;
Wang et al., 2009). Two hallmarks of DC maturation, namely
dendrite outgrowth and MHC class II expression, were sig-
niﬁcantly reduced in RBP-J-deﬁcient DCs during LPS-me-
diated maturation (Wang et al., 2009). Additionally, RBP-J-
deﬁcient DCs stimulated signiﬁcantly weaker T cell prolifer-
ation than control cells. Pathogen-mediated DC maturation
is associated with chemokine receptor expression and LPS-
mediated CXCR4 expression was decreased in RBP-J-de-
ﬁcient DCs. Over-expression of CXCR4 rescued the matu-
ration defects of RBP-J-deﬁcient DCs by restoring dendrite
outgrowth and MHC II expression. Activation of Notch sig-
naling using DLL1 upregulated surface expression of
CXCR4 and promoted DC maturation, and these ﬁndings
were reversed using a GSI (Wang et al., 2009).
Further studies from the Han laboratory outlined a role for
Notch signaling in theanti-tumor functionofDCs. LossofRBP-
J in DCs impaired DC-dependent anti-tumor responses (Feng
et al., 2010). RBP-J-deﬁcient DCs were unable to repress
tumor growth when co-injected with tumor cells in mice and
their capacity to recruit T cells to solid tumors and draining
lymph nodes was compromised. In addition, RBP-J-deﬁcient
DCs exhibited attenuated expression of the antigen present-
ing molecules MHC II, co-stimulatory molecules CD80 and
CD86 in response to tumor antigens and displayed a reduced
capacity to activate T cells in relation to T cell proliferation,
T cell cytokine production (IFNγ and IL-4) and cytotoxicity
(Feng et al., 2010). Taken together, these results demonstrate
clear involvement of Notch-RBP-J signaling in DCmaturation
and in the execution of DC-mediated T cell activation in the
setting of both infection and tumor immunity.
Notch signaling in macrophage activation
Macrophages are versatile cells with diverse functions in
inﬂammation, tissue remodeling, angiogenesis and tumor
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immunity. They respond to a wide variety of environmental
cues to regulate immunity and inﬂammation by sensing
microbial pathogens, secreting cytokines and inﬂammatory
mediators and presenting antigen to T cells. Similar to DCs,
macrophages distinguish pathogens and self antigens
through PRRs of the TLR, NLR, and RLR families. Upon
PAMP recognition, TLRs engage TIR-containing adaptor
molecules and kinases that trigger signaling pathways
resulting in the activation of transcription factors, including
NF-κB, IFN-regulatory factors (IRFs) and AP-1. This leads to
the induction of proinﬂammatory cytokines such as IL-1,
TNFα, IL-6, type I (α and β) IFNs, and immunoregulatory
cytokines including IL-12 and IL-10. Unrestrained activation
of TLR signaling can lead to excessive inﬂammation and
tissue damage and contribute to sepsis, chronic inﬂamma-
tion, autoimmune disease and cancer. In addition to TLR-
mediated PAMP recognition, macrophages can also be
activated by IFNγ stimulation. IFNγ synergizes with TLRs to
induce augmented production of inﬂammatory cytokines (Hu
and Ivashkiv, 2009).
Recent studies have delineated a role for canonical Notch
signaling during macrophage activation (Fig. 3). Indeed,
constitutive expression of Notch pathway components has
been detected on primary macrophages and established
macrophage cell lines of both human and mouse origin
(Zhang et al., 2010; Fung et al., 2007; Foldi et al., 2010;
Monsalve et al., 2006; Hu et al., 2008). Notch receptor,
ligand and target gene expression can be further enhanced
in macrophages in response to proinﬂammatory stimuli,
including various TLR ligands (Fung et al., 2007; Ito et al.,
2009; Foldi et al., 2010; Monsalve et al., 2006; Monsalve
et al., 2009; Palaga et al., 2008; Hu et al., 2008; Tsao et al.,
2011; Outtz et al., 2010; Goh et al., 2009), activated lym-
phocyte-derived DNA (ALD-DNA) (Zhang et al., 2010),
inﬂuenza infection (Ito et al., 2011), Mycobacterium bovis
Bacille Calmette-Guérin (M. bovis BCG) infection (Narayana
and Balaji 2008; Bansal et al., 2009; Kapoor et al., 2010) or
stimulation with helminth antigens (Goh et al., 2009).
Numerous lines of evidence from studies employing
genetic or RNAi-mediated disruption of Notch pathway
components, inhibition of Notch receptor cleavage using
GSIs or gain-of-function studies expressing constitutively
active NICD, support a positive role for canonical Notch
signaling during the inﬂammatory response in activated
macrophages. Firstly, over-expression of NICD1 in
Raw264.7 cells increased STAT1 activation and STAT1-de-
pendent transcription in response to LPS and IFNγ, leading
to higher expression of molecules characteristic of mature
activated macrophages (Monsalve et al., 2006; Monsalve
et al., 2009). Secondly using a similar gain-of-function
approach, Raw264.7 cells over-expressing NICD1 exhibited
increased expression of the cytokines TNFα and IL-6 and
the enzyme iNOS (Monsalve et al., 2009). NICD1 expression
also upregulated both basal and LPS-induced NF-κB acti-
vation, as demonstrated by increased phosphorylation and
degradation of IκBα, increased nuclear translocation of
NF-κB and enhanced binding of NF-κB subunits to the TNFα
and iNOS promoters. Inhibiting Notch signaling with the GSI
DAPT or shRNA for Notch1 abrogated NF-κB activity fol-
lowing LPS stimulation (Monsalve et al., 2009). Thus, one
potential mechanism whereby Notch signaling contributes to
the inﬂammatory response is by enhancing NF-κB signaling.
In support of these ﬁndings, Notch signaling inhibition in
primary BMDMs using another GSI, IL-CHO, decreased LPS
Hes1 Hey1













Figure 3. Crosstalk between the TLR signaling pathway and the Notch pathway. Expression and/or function of various
components of the Notch pathways could be regulated by TLR signaling. Conversely, Notch pathway components positively or
negatively modulate TLR-activated transcriptional, translational, and metabolic programs to ﬁnetune outcomes of immune responses.
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plus IFNγ-mediated induction of IL-6, iNOS, and TNFα
expression (Palaga et al., 2008). In addition, both IL-CHO or
siRNA for Notch1 decreased translocation of NF-κB into the
nucleus upon stimulation with LPS/IFNγ in Raw264.7 cells
(Palaga et al., 2008). Treatment with the GSI DAPT was
shown to attenuate LPS-mediated IL-1β and IL-6 in
Raw264.7 cells and decrease the levels of these cytokines in
an in vivo sepsis model (Tsao et al., 2011). These results
were conﬁrmed and extended by our laboratory using a
rigorous genetic approach demonstrating that deletion of
RBP-J in the myeloid compartment attenuated TLR-induced
expression of key inﬂammatory mediators including TNFα,
IL-6, IL-12, and iNOS (Hu et al., 2008; Xu et al., 2012).
Mechanisms of Notch-regulated macrophage gene expres-
sion may involve: 1) Direct binding of RBP-J to gene pro-
moters supported by observations that a mutation in the
putative RBP-J element in the IL-6 promoter diminished
LPS-driven IL-6 reporter gene activity (Hu et al., 2008). 2)
Indirect regulation via promoting translation of transcription
factors required for gene activation such as IRF8 (Xu et al.,
2012). 3) Reprogramming mitochondria metabolic status to
link Notch signaling with metabolic pathways (Xu et al.,
2015). Functionally, RBP-J deﬁciency protected mice from
lethality following endotoxin challenge (Hu et al., 2008) and
comprised host defense to bacterial pathogens in vivo (Xu
et al., 2012). Furthermore, RBP-J-deﬁcient macrophages
displayed attenuated capacity to activate Tcells (Wang et al.,
2010). Thus, Notch signaling via the canonical Notch-RBP-J
pathway contributes to TLR-induced cytokine gene expres-
sion during inﬂammatory macrophage activation.
Consistent with this hypothesis, involvement of Notch
signaling in the inﬂammatory response in the context of
wound healing has been described by Outtz et al. (2010).
Decreased macrophage recruitment and TNFα expression
was observed in wounds of mice with myeloid-speciﬁc inhi-
bition of Notch1 compared to wild type controls. Experiments
incorporating GSIs or NICD1 over-expression demonstrated
that canonical Notch signaling mediates LPS/IFNγ-induced
VEGFR-1 expression, which is important for the recruitment
and function of macrophages during angiogenesis and
inﬂammation. Similar to the studies outlined above,
LPS/IFNγ-mediated cytokine induction was attenuated in
Notch1-deﬁcient macrophages (Outtz et al., 2010). In an
experimental model for systemic lupus erythematosus
(SLE), blocking Notch signaling using the GSI DAPT atten-
uated induction of inﬂammatory cytokines and cell surface
markers in Raw264.7 cells treated with ALD-DNA (Zhang
et al., 2010). GSI treatment also inhibited the antigen pre-
senting capabilities of ALD-DNA-stimulated BMDMs (Zhang
et al., 2010), strengthening the role for the Notch-RBP-J
pathway during the inﬂammatory response.
Notch1 has been implicated in M. bovis BCG infection-
mediated induction of Suppressor of cytokine signaling
(SOCS) 3, which is a critical negative regulator of cytokine
signaling (Narayana and Balaji, 2008). GSI-I treatment
inhibited SOCS3 induction by M. bovis BCG in mouse
peritoneal macrophages. Similar results were obtained using
siNotch1 in Raw264.7 cells. NICD1 over-expression poten-
tiated SOCS3 induction in response to M. bovis BCG. This
group subsequently outlined a role for Notch signaling in
M. bovis BCG-mediated up-regulation of cyclooxygenase-2
(COX2) (Bansal et al., 2009) and matrix metalloproteinase-9
(MMP9) (Kapoor et al., 2010), an effector molecule that
participates in cell motility during inﬂammatory responses.
Raw264.7 cells over-expressing NICD1 exhibited increased
COX2 and MMP9 induction in response to M. bovis BCG
infection, while siNotch1 or GSI-I treatment blocked this
effect. Increased expression of NICD1, Hes1 and MMP9 was
detected in brain tissue samples from patients with tuber-
culosis meningitis (Kapoor et al., 2010). These studies pro-
vide insight into the role of Notch signaling in host-
mycobacteria interactions.
In contrast with the ﬁndings described above, Zhang et al.,
have described the inhibitory role for Notch during TLR-me-
diated inﬂammatory responses in macrophages (Zhang et al.,
2012). TLR-mediated induction of IL-6 andTNFαwas reduced
upon over-expression of NICD1 or NICD2 inmouse peritoneal
macrophages (Zhang et al., 2012). Induction of the anti-in-
ﬂammatory cytokine IL-10 was enhanced in this experimental
model. Loss-of-function experiments where Notch1 expres-
sion was inhibited using siRNA or GSI X treatment, led to
increased TNFα and IL-6 production and decreased IL-10.
Notch signaling was suggested to exert the observed inhibi-
tory effects by attenuating TLR-mediated ERK phosphoryla-
tion and NF-κB transcriptional activity (Zhang et al., 2012).
Importantly, in the context of tumor immunity, depletion of
RBP-J in tumor associated macrophages (TAMs) compro-
mises TAM differentiation and function and restores tumor-
inﬁltrating cytotoxic T cell responses (Franklin et al., 2014),
suggesting a suppressive role of Notch signaling in anti-tumor
immune effector functions.
Several possible reasons may explain the discrepancies
between these reports and the previous work outlining a
positive role for Notch signaling during TLR-mediated mac-
rophage activation. Different GSIs were used in the various
studies including DAPT (Monsalve et al., 2009; Tsao et al.,
2011), IL-CHO (Palaga et al., 2008), GSI-I (Narayana and
Balaji 2008; Bansal et al., 2009) GSI IX (Wang et al., 2010)
or GSI X (Tsao et al., 2011) and GSIs have been shown to
affect signaling pathways in addition to Notch (Hass et al.,
2009). Additionally, different cell models from different spe-
cies were used in the various studies, namely mouse
Raw264.7 cells, mouse BMDMs and peritoneal macro-
phages, rat primary alveolar macrophages or human PBMC-
derived macrophages. The speciﬁc outcome of simultane-
ous Notch and TLR stimulation in macrophages is likely to
involve a tightly regulated balance between positive and
negative regulatory signals in a cell context and Notch
ligand-speciﬁc fashion. Further studies into global Notch-
RBP-J target identiﬁcation using these approaches in innate
immune cells will provide valuable insights into the functional
role of Notch signaling in the inﬂammatory setting.
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Notch signaling in other cell types
The skin epidermis represents a physical barrier that pro-
tects against infectious agents and mechanical injury. Ker-
atinocytes are the main epithelial cell type that generates the
epidermal layer of the skin. Epidermal homeostasis and
barrier integrity is maintained through the coordinated reg-
ulation of proliferation, migration and cell death. During epi-
dermal inﬂammation, homeostasis collapses resulting in the
production of alarmins by keratinocytes and the recruitment
of immune cells to the site of tissue damage. One such alarm
signal is thymic stromal lymphoprotein (TSLP), which is an
IL-7-like cytokine produced by epithelial cells and is con-
sidered a general biomarker for skin barrier defects. TSLP
expression is sustained as long as barrier defect persists,
thus TSLP-mediated activation of dermal innate immune
cells and the subsequent local cellular immune response is
thought to contribute to the pathogenesis of eczema/atopic
dermatitis (AD) (Blanpain et al., 2006).
Notch signaling has been demonstrated to sustain the
epidermal barrier by supporting keratinocyte terminal differ-
entiation (Blanpain et al., 2006; Rangarajan et al., 2001).
Furthermore, emerging evidence suggests an important role
for Notch in preventing inﬂammatory skin disease and
maintaining epidermal homeostasis. The ablation of canon-
ical Notch signaling in keratinocytes by simultaneous dele-
tion of both Notch1 and Notch2 or RBP-J resulted in
defective skin barrier function and increased expression of
TSLP, leading to the development of a severe AD-like skin
phenotype in mice (Demehri et al., 2008; Dumortier et al.,
2010). Interestingly, the AD-like inﬂammation associated
with Notch deﬁciency was accompanied by G-CSF-induced
myeloproliferative disorder (MPD) characterized by an
increase in immature myeloid populations in the bone mar-
row and spleen (Dumortier et al., 2010), suggesting a pro-
tective role for Notch against myeloproliferation similar to
that observed by Klinakis et al. (2011).
Individuals with severe AD are at increased risk of
developing the chronic lung disease allergic asthma, a pro-
gression termed atopic march (Demehri et al., 2008).
Demehri et al., demonstrated that AD-like disease resulting
from deletion of RBP-J in the skin predisposed mice to
allergic asthma in an ovalbumin model of allergic inﬂam-
mation. As RBP-J was not deleted in the lung, these data
show that the skin barrier defect served as a primary risk
factor for development of asthma in the normal lung
(Demehri et al., 2008). TSLP was required for asthma sus-
ceptibility in animals with the AD-like pathology, as deletion
of the TLSP receptor in RBP-J-deﬁcient mice blocked the
progression from allergic skin inﬂammation to asthma. Using
a gain-of-function approach, TSLP overexpression in epi-
dermal keratinocytes conferred an asthmatic phenotype
(Demehri et al., 2008). These ﬁndings indicate that Notch-
RBP-J-mediated suppression of TSLP prevents inﬂamma-
tory skin disease and the associated risk of progression to
allergic asthma.
Murthy et al., have provided additional evidence for
Notch-mediated regulation of skin barrier immunity by
investigating the role of the protease ADAM17 (also called
TACE) (Murthy et al., 2012). As mentioned earlier, ADAM-
mediated cleavage of Notch receptors is a one of the key
steps in the activation of Notch signaling (Kopan and Ilagan,
2009). Similar to simultaneous ablation of Notch1 and
Notch2 or RBP-J (Dumortier et al., 2010), ADAM17 inacti-
vation in the keratinocyte compartment resulted in increased
epidermal TSLP expression and spontaneous onset of AD
and MPD in mice (Murthy et al., 2012). Ectopic activation of
Notch rescued local skin inﬂammation and MPD in ADAM17-
deﬁcient mice. Notch was shown to inhibit AP-1-mediated
induction of TSLP by antagonizing recruitment of the AP-1
subunit c-Fos to the TSLP promoter (Murthy et al., 2012).
This observation that Notch inhibits AP-1 activity is in
keeping with studies by Monsalve et al., demonstrating
decreased AP-1 driven transcriptional activity in response to
proinﬂammatory stimuli in macrophages over-expressing
NICD1 (Monsalve et al., 2006; Monsalve et al., 2009).
ADAM17 was found to play a role in basal Notch activa-
tion in the adult epidermis as decreased levels of NICD and
Notch target genes (Hes5, Hey1, and Hey2) were detected
in keratinocytes from the ADAM17-deﬁcient mice (Murthy
et al., 2012). Although both ADAM10 and ADAM17 have
been reported to cleave Notch receptors and facilitate NICD
release by γ-secretase, there is controversy over the speciﬁc
ADAM involved. Bozkulak et al., demonstrated that although
Notch1 was a substrate for both ADAM10 and ADAM17, the
speciﬁc protease required for NICD activation was context
dependent, with ADAM10 absolutely required for Notch1
signaling in response to Notch ligands, while ligand-inde-
pendent activation was regulated by ADAM17 (Bozkulak and
Weinmaster, 2009). In vivo studies have shown that
ADAM10 is essential for Notch2 activation (Gibb et al.,
2010). Murthy et al., demonstrated that the ADAM17-medi-
ated Notch activation in keratinocytes occurred in a ligand-
independent manner (Murthy et al., 2012). NICD generation
and Notch target gene expression in response to EDTA or
increased calcium exposure was blocked in ADAM17-deﬁ-
cient keratinocytes but was unaffected in cells stimulated
with the Notch ligand DLL4 (Murthy et al., 2012). The
developmental context of Notch activation is likely to be
facilitated by ADAM10, as keratintocyte development was
inhibited in mice lacking epidermal ADAM10 (Weber et al.,
2010). ADAM17 deletion on the other hand did not affect
keratinoctye differentiation in this study (Weber et al., 2010).
Murthy et al., propose a ligand-independent Notch signaling
model, whereby ADAM17 controls barrier homeostasis and
immunity in their experimental system, but not keratinocyte
development (Murthy et al., 2012).
Taken together, these reports indicated that blocking
Notch signaling leads to increased TSLP induction and AD in
mice. In support of this hypothesis, expression of Notch
receptors was downregulated in clinical skin samples from
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AD patients (Dumortier et al., 2010) and gene expression
analysis of publicly available microarray data revealed dif-
ferential expression of Notch2, Notch3 and presenelin1 in
patients with AD and psoriasis (Murthy et al., 2012). The AD-
like phenotype observed upon inactivation of Notch pathway
components in mice keratinocytes was associated with
asthma progression and MPD. Thus, Notch signaling plays a
key role in maintenance of healthy epithelial barrier integrity
and may decrease the risk of AD-associated MPD or asthma
development.
CONCLUSIONS
Due to the key role of Notch in these fundamental cell pro-
cesses, dysregulated Notch signaling is associated with a
number of human disorders, including developmental syn-
dromes and cancer. More recently, polymorphisms in genes
associated with Notch signaling have been linked to
rheumatoid arthritis (Stahl et al., 2010), suggesting a previ-
ously unappreciated connection between Notch and
autoimmunity. Although much remains to be learned about
the role of Notch in inﬂammatory conditions, the rapidly
accumulating body of literature strongly favors the notion
that the Notch pathway is a critical regulator of innate
immunity and inﬂammation. There is an emerging pattern of
reciprocal regulation between Notch signaling and inﬂam-
mation in that inﬂammatory stimuli activate myeloid Notch
signaling and Notch signaling in myeloid cells in turn mod-
ulates inﬂammatory responses. As the Notch pathway is
easily amenable to pharmacological manipulations such as
γ-secretase inhibitors and metalloprotease inhibitors, tar-
geting Notch signaling may represent a new and promising
approach to modulating inﬂammation in relevant disease
states. Moreover, availability of reagents that can target
speciﬁc Notch receptors makes it possible to further focus
the speciﬁcity of treatment (Wu et al., 2010). Indeed, thera-
pies targeting the Notch pathway have shown efﬁcacy in
animal models of SLE and inﬂammatory arthritis (Park et al.,
2015; Zhang et al., 2010; Sekine et al., 2012). Apparently,
there might be a long way to go before the ﬁeld appreciates
the Notch pathway as a key regulator of inﬂammation among
other well-established players and fully embraces the idea of
Notch signaling in acute responses besides its role in
immune cell development.
ACKNOWLEDGEMENTS
XH is supported by the National Basic Research Program (973
Program) (No. 2015CB943201), National Natural Science Founda-
tion of China Young Investigator Award 81422019, and funds from
Peking-Tsinghua Center of Life Sciences.
ABBREVIATIONS
AD, atopic dermatitis; CMML, chronic myelomonocytic leukemia;
COX2, cyclooxygenase-2; DCs, dendritic cells; EGF, epidermal
growth factor; G-CSF, granulocyte colony-stimulating factor; GM-
CSF, granulocyte macrophage colony stimulating factor; HDACs,
histone deacetylases; HSCs, hematopoietic stem cells; IFNγ,
interferon-γ; IKKs, inhibitor of NF-κB kinases; IL-1β, interlukin-1β;
MAPKs, mitogen-activated protein kinases; MMP9, matrix metallo-
proteinase-9; MPD, myeloproliferative disorder; NICD, Notch intra-
cellular domain; PAMPs, pathogen-associated molecular patterns;
PRRs, pattern recognition receptors; RA, rheumatoid arthritis; SLE,
systemic lupus erythematosus; TAMs, tumor associated macro-
phages; TLRs, toll-like receptors; TSLP, thymic stromal
lymphoprotein.
COMPLIANCE WITH ETHICS GUIDELINES
Yingli Shang, Sinead Smith, and Xiaoyu Hu declare that they have
no conﬂict of interest. This article does not contain any studies with
human or animal subjects performed by the any of the authors.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
Aguilera C, Hoya-Arias R, Haegeman G, Espinosa L, Bigas A (2004)
Recruitment of IkappaBalpha to the hes1 promoter is associated with
transcriptional repression. Proc Natl Acad Sci USA 101:16537–16542
Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T et al (2004)
Instruction of distinct CD4 T helper cell fates by different notch
ligands on antigen-presenting cells. Cell 117:515–526
Amsen D, Antov A, Jankovic D, Sher A, Radtke F et al (2007) Direct
regulation of Gata3 expression determines the T helper differen-
tiation potential of Notch. Immunity 27:89–99
Ando K, Kanazawa S, Tetsuka T, Ohta S, Jiang X et al (2003)
Induction of Notch signaling by tumor necrosis factor in rheuma-
toid synovial ﬁbroblasts. Oncogene 22:7796–7803
Aoyama T, Takeshita K, Kikuchi R, Yamamoto K, Cheng XW et al
(2009) gamma-Secretase inhibitor reduces diet-induced
atherosclerosis in apolipoprotein E-deﬁcient mice. Biochem
Biophys Res Commun 383:216–221
Bai S, Kopan R, Zou W, Hilton MJ, Ong CT et al (2008) NOTCH1
regulates osteoclastogenesis directly in osteoclast precursors and
indirectly via osteoblast lineage cells. J Biol Chem 283:6509–6518
Bansal K, Narayana Y, Patil SA, Balaji KN (2009) M. bovis BCG
induced expression of COX-2 involves nitric oxide-dependent
and -independent signaling pathways. J Leukoc Biol 85:804–816
Bigas A, Martin DI, Milner LA (1998) Notch1 and Notch2 inhibit
myeloid differentiation in response to different cytokines. Mol Cell
Biol 18:2324–2333
Bigas A, Robert-Moreno A, Espinosa L (2010) The Notch pathway in
the developing hematopoietic system. Int J DevBiol 54:1175–1188
REVIEW Yingli Shang et al.









Blanpain C, Lowry WE, Pasolli HA, Fuchs E (2006) Canonical notch
signaling functions as a commitment switch in the epidermal
lineage. Genes Dev 20:3022–3035
Borggrefe T, Oswald F (2009) The Notch signaling pathway:
transcriptional regulation at Notch target genes. Cell Mol Life
Sci 66:1631–1646
Bozkulak EC, Weinmaster G (2009) Selective use of ADAM10 and
ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29:5679–
5695
Carlesso N, Aster JC, Sklar J, Scadden DT (1999) Notch1-induced
delay of human hematopoietic progenitor cell differentiation is
associated with altered cell cycle kinetics. Blood 93:838–848
Caton ML, Smith-Raska MR, Reizis B (2007) Notch-RBP-J signaling
controls the homeostasis of CD8- dendritic cells in the spleen.
J Exp Med 204:1653–1664
Cheng P, Gabrilovich D (2008) Notch signaling in differentiation and
function of dendritic cells. Immunol Res 41:1–14
Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B et al (2001)
Notch-1 regulates NF-kappaB activity in hemopoietic progenitor
cells. J Immunol 167:4458–4467
Cheng P, Nefedova Y, Miele L, Osborne BA, Gabrilovich D (2003)
Notch signaling is necessary but not sufﬁcient for differentiation of
dendritic cells. Blood 102:3980–3988
Cheng P, Nefedova Y, Corzo CA, Gabrilovich DI (2007) Regulation
of dendritic-cell differentiation by bone marrow stroma via
different Notch ligands. Blood 109:507–515
Dees C, Zerr P, Tomcik M, Beyer C, Horn A et al (2011) Inhibition of
Notch signaling prevents experimental ﬁbrosis and induces
regression of established ﬁbrosis. Arthritis Rheum 63:1396–1404
Demehri S, Liu Z, Lee J, Lin MH, Crosby SD et al (2008) Notch-
deﬁcient skin induces a lethal systemic B-lymphoproliferative
disorder by secreting TSLP, a sentinel for epidermal integrity.
PLoS Biol 6:e123
Dontje W, Schotte R, Cupedo T, Nagasawa M, Scheeren F et al
(2006) Delta-like1-induced Notch1 signaling regulates the human
plasmacytoid dendritic cell versus T-cell lineage decision through
control of GATA-3 and Spi-B. Blood 107:2446–2452
Dumortier A, Durham AD, Di Piazza M, Vauclair S, Koch U et al
(2010) Atopic dermatitis-like disease and associated lethal
myeloproliferative disorder arise from loss of Notch signaling in
the murine skin. PLoS One 5:e9258
EagarTN,TangQ,WolfeM,HeY,PearWSet al (2004)Notch1signaling
regulates peripheral Tcell activation. Immunity 20:407–415
Engin F, Yao Z, Yang T, ZhouG, Bertin Tet al (2008) Dimorphic effects
of Notch signaling in bone homeostasis. Nat Med 14:299–305
Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Statnikov A et al (2010)
The Notch/Hes1 pathway sustains NF-kappaB activation through
CYLD repression in T cell leukemia. Cancer Cell 18:268–281
Fang TC, Yashiro-Ohtani Y, Del Bianco C, Knoblock DM, Blacklow
SC et al (2007) Notch directly regulates Gata3 expression during
T helper 2 cell differentiation. Immunity 27:100–110
Feng F, Wang YC, Hu XB, Liu XW, Ji G et al (2010) The transcription
factor RBP-J-mediated signaling is essential for dendritic cells to
evoke efﬁcient anti-tumor immune responses in mice. Mol Cancer
9:90
Ferrero I, Held W, Wilson A, Tacchini-Cottier F, Radtke F et al (2002)
Mouse CD11c(+) B220(+) Gr1(+) plasmacytoid dendritic cells
develop independently of the T-cell lineage. Blood 100:2852–
2857
Foldi J, Chung AY, Xu H, Zhu J, Outtz HH et al (2010) Autoampli-
ﬁcation of Notch signaling in macrophages by TLR-induced and
RBP-J-dependent induction of Jagged1. J Immunol 185:5023–
5031
Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR et al (2014) The
cellular and molecular origin of tumor-associated macrophages.
Science 344:921–925
Fukushima H, Nakao A, Okamoto F, Shin M, Kajiya H et al (2008)
The association of Notch2 and NF-kappaB accelerates RANKL-
induced osteoclastogenesis. Mol Cell Biol 28:6402–6412
Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF
et al (2007) Delta-like 4 induces notch signaling in macrophages:
implications for inﬂammation. Circulation 115:2948–2956
Gibb DR, El Shikh M, Kang DJ, Rowe WJ, El Sayed R et al (2010)
ADAM10 is essential for Notch2-dependent marginal zone B cell
development and CD23 cleavage in vivo. J Exp Med 207:623–
635
Goh F, Irvine KM, Lovelace E, Donnelly S, Jones MK et al (2009)
Selective induction of the Notch ligand Jagged-1 in macrophages
by soluble egg antigen from Schistosoma mansoni involves ERK
signalling. Immunology 127:326–337
Hamidi H, Gustafason D, Pellegrini M, Gasson J (2011) Identiﬁcation
of novel targets of CSL-dependent Notch signaling in hematopoi-
esis. PLoS One 6:e20022
Han W, Ye Q, Moore MA (2000) A soluble form of human Delta-like-1
inhibits differentiation of hematopoietic progenitor cells. Blood
95:1616–1625
Hass MR, Sato C, Kopan R, Zhao G (2009) Presenilin: RIP and
beyond. Semin Cell Dev Biol 20:201–210
Hilton MJ, Tu X, Wu X, Bai S, Zhao H et al (2008) Notch signaling
maintains bone marrow mesenchymal progenitors by suppress-
ing osteoblast differentiation. Nat Med 14:306–314
Hoffman C, Park SH, Daley E, Emson C, Louten J et al (2011)
Interleukin-19: a constituent of the regulome that controls antigen
presenting cells in the lungs and airway responses to microbial
products. PLoS One 6:e27629
Hoyne GF, Le Roux I, Corsin-Jimenez M, Tan K, Dunne J et al
(2000) Serrate1-induced notch signalling regulates the decision
between immunity and tolerance made by peripheral CD4(+) T
cells. Int Immunol 12:177–185
Hu X, Ivashkiv LB (2009) Cross-regulation of signaling pathways by
interferon-gamma: implications for immune responses and
autoimmune diseases. Immunity 31:539–550
Hu X, Chung AY, Wu I, Foldi J, Chen J et al (2008) Integrated
regulation of Toll-like receptor responses by Notch and interferon-
gamma pathways. Immunity 29:691–703
Ishii H, Nakazawa M, Yoshino S, Nakamura H, Nishioka K et al
(2001) Expression of notch homologues in the synovium of
rheumatoid arthritis and osteoarthritis patients. Rheumatol Int
21:10–14
Iso T, Kedes L, Hamamori Y (2003) HES and HERP families:
multiple effectors of the Notch signaling pathway. J Cell Physiol
194:237–255
Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M et al
(2009) TLR9 regulates the mycobacteria-elicited pulmonary
Notch signaling in inﬂammatory responses REVIEW









granulomatous immune response in mice through DC-derived
Notch ligand delta-like 4. J Clin Invest 119:33–46
Ito T, Allen RM, Carson WFT, Schaller M, Cavassani KA et al (2011)
The critical role of Notch ligand Delta-like 1 in the pathogenesis of
inﬂuenza A virus (H1N1) infection. PLoS Pathog 7:e1002341
Izon DJ, Aster JC, He Y, Weng A, Karnell FG et al (2002) Deltex1
redirects lymphoid progenitors to the B cell lineage by antago-
nizing Notch1. Immunity 16:231–243
Jaiswal MK, Agrawal V, Pamarthy S, Katara GK, Kulshrestha A et al
(2015) Notch Signaling in Inﬂammation-Induced Preterm Labor.
Sci Rep 5:15221
Jiao Z, Wang W, Guo M, Zhang T, Chen L et al (2010) Expression
analysis of Notch-related molecules in peripheral blood T helper
cells of patients with rheumatoid arthritis. Scand J Rheumatol
39:26–32
Kapoor N, Narayana Y, Patil SA, Balaji KN (2010) Nitric oxide is
involved in Mycobacterium bovis Bacillus calmette-guerin-acti-
vated Jagged1 and Notch1 signaling. J Immunol 184:3117–3126
Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H et al (2011) A
novel tumour-suppressor function for the Notch pathway in
myeloid leukaemia. Nature 473:230–233
Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway:
unfolding the activation mechanism. Cell 137:216–233
Kumano K, Chiba S, Shimizu K, Yamagata T, Hosoya N et al (2001)
Notch1 inhibits differentiation of hematopoietic cells by sustaining
GATA-2 expression. Blood 98:3283–3289
Lam LT, Ronchini C, Norton J, Capobianco AJ, Bresnick EH (2000)
Suppression of erythroid but not megakaryocytic differentiation of
human K562 erythroleukemic cells by notch-1. J Biol Chem
275:19676–19684
Lewis KL, Caton ML, Bogunovic M, Greter M, Grajkowska LT et al
(2011) Notch2 receptor signaling controls functional differentia-
tion of dendritic cells in the spleen and intestine. Immunity
35:780–791
Li S, Miller CH, Giannopoulou E, Hu X, Ivashkiv LB et al (2014) RBP-
J imposes a requirement for ITAM-mediated costimulation of
osteoclastogenesis. J Clin Invest 124:5057–5073
Maekawa Y, Tsukumo S, Chiba S, Hirai H, Hayashi Y et al (2003)
Delta1-Notch3 interactions bias the functional differentiation of
activated CD4+ T cells. Immunity 19:549–559
Maillard I, Fang T, Pear WS (2005) Regulation of lymphoid
development, differentiation, and function by the Notch pathway.
Annu Rev Immunol 23:945–974
Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N et al
(2011) Crosstalk between the canonical NF-kappaB and Notch
signaling pathways inhibits Ppargamma expression and pro-
motes pancreatic cancer progression in mice. J Clin Invest
121:4685–4699
Martinez Arias A, Zecchini V, Brennan K (2002) CSL-independent
Notch signalling: a checkpoint in cell fate decisions during
development? Curr Opin Genet Dev 12:524–533
Milner LA, Bigas A, Kopan R, Brashem-Stein C, Bernstein ID et al
(1996) Inhibition of granulocytic differentiation by mNotch1. Proc
Natl Acad Sci USA 93:13014–13019
Mizutani K, Matsubayashi T, Iwase S, Doi TS, Kasai K et al (2000)
Murine Delta homologue, mDelta1, expressed on feeder cells
controls cellular differentiation. Cell Struct Funct 25:21–31
Monsalve E, Perez MA, Rubio A, Ruiz-Hidalgo MJ, Baladron V et al
(2006) Notch-1 up-regulation and signaling following macro-
phage activation modulates gene expression patterns known to
affect antigen-presenting capacity and cytotoxic activity.
J Immunol 176:5362–5373
Monsalve E, Ruiz-Garcia A, Baladron V, Ruiz-Hidalgo MJ, Sanchez-
Solana B et al (2009) Notch1 upregulates LPS-induced macro-
phage activation by increasing NF-kappaB activity. Eur J
Immunol 39:2556–2570
Murea M, Park JK, Sharma S, Kato H, Gruenwald A et al (2010)
Expression of Notch pathway proteins correlates with albumin-
uria, glomerulosclerosis, and renal function. Kidney Int 78:514–
522
Murthy A, Shao YW, Narala SR, Molyneux SD, Zuniga-Pﬂucker JC
et al (2012) Notch Activation by the Metalloproteinase ADAM17
Regulates Myeloproliferation and Atopic Barrier Immunity by
Suppressing Epithelial Cytokine Synthesis. Immunity 36:105–119
Nakazawa M, Ishii H, Aono H, Takai M, Honda T et al (2001a) Role
of Notch-1 intracellular domain in activation of rheumatoid
synoviocytes. Arthritis Rheum 44:1545–1554
Nakazawa M, Ishii H, Nakamura H, Yoshino SI, Fukamizu A et al
(2001b) NFkappaB2 (p52) promoter activation via Notch
signaling pathway in rheumatoid synoviocytes. Int J Mol Med
7:31–35
Narayana Y, Balaji KN (2008) NOTCH1 up-regulation and signaling
involved in Mycobacterium bovis BCG-induced SOCS3 expres-
sion in macrophages. J Biol Chem 283:12501–12511
Ohishi K, Varnum-Finney B, Serda RE, Anasetti C, Bernstein ID
(2001) The Notch ligand, Delta-1, inhibits the differentiation of
monocytes into macrophages but permits their differentiation into
dendritic cells. Blood 98:1402–1407
Olivier A, Lauret E, Gonin P, Galy A (2006) The Notch ligand delta-1
is a hematopoietic development cofactor for plasmacytoid den-
dritic cells. Blood 107:2694–2701
Ong CT, Sedy JR, Murphy KM, Kopan R (2008) Notch and presenilin
regulate cellular expansion and cytokine secretion but cannot
instruct Th1/Th2 fate acquisition. PLoS One 3:e2823
Osborne BA, Minter LM (2007) Notch signalling during peripheral
T-cell activation and differentiation. Nat Rev Immunol 7:64–75
Osipo C, Golde TE, Osborne BA, Miele LA (2008) Off the beaten
pathway: the complex cross talk between Notch and NF-kappaB.
Lab Invest 88:11–17
Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P et al
(2006) Treg-mediated immunosuppression involves activation of
the Notch-HES1 axis by membrane-bound TGF-beta. J Clin
Invest 116:996–1004
Ottaviani S, Tahiri K, Frazier A, Hassaine ZN, Dumontier MF et al
(2010) Hes1, a new target for interleukin 1beta in chondrocytes.
Ann Rheum Dis 69:1488–1494
Outtz HH, Wu JK, Wang X, Kitajewski J (2010) Notch1 deﬁciency
results in decreased inﬂammation during wound healing and
regulates vascular endothelial growth factor receptor-1 and
inﬂammatory cytokine expression in macrophages. J Immunol
185:4363–4373
Palaga T, Buranaruk C, Rengpipat S, Fauq AH, Golde TE et al
(2008) Notch signaling is activated by TLR stimulation and
regulates macrophage functions. Eur J Immunol 38:174–183
REVIEW Yingli Shang et al.









Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ et al (2006)
NOTCH1 directly regulates c-MYC and activates a feed-forward-
loop transcriptional network promoting leukemic cell growth. Proc
Natl Acad Sci USA 103:18261–18266
Park JS, Kim SH, Kim K, Jin CH, Choi KY et al (2015) Inhibition of
notch signalling ameliorates experimental inﬂammatory arthritis.
Ann Rheum Dis 74:267–274
Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J et al (1999)
Deﬁcient T cell fate speciﬁcation in mice with an induced
inactivation of Notch1. Immunity 10:547–558
Radtke F, Ferrero I, Wilson A, Lees R, Aguet M et al (2000) Notch1
deﬁciency dissociates the intrathymic development of dendritic
cells and T cells. J Exp Med 191:1085–1094
Radtke F, Fasnacht N, Macdonald HR (2010) Notch signaling in the
immune system. Immunity 32:14–27
Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C et al
(2001) Notch signaling is a direct determinant of keratinocyte
growth arrest and entry into differentiation. EMBO J 20:3427–
3436
Sathe P, Wu L (2011) The network of cytokines, receptors and
transcription factors governing the development of dendritic cell
subsets. Protein Cell 2:620–630
Schaller MA, Neupane R, Rudd BD, Kunkel SL, Kallal LE et al
(2007) Notch ligand Delta-like 4 regulates disease pathogenesis
during respiratory viral infections by modulating Th2 cytokines.
J Exp Med 204:2925–2934
Schroeder T, Just U (2000) Notch signalling via RBP-J promotes
myeloid differentiation. EMBO J 19:2558–2568
Sekine C, Moriyama Y, Koyanagi A, Koyama N, Ogata H et al (2009)
Differential regulation of splenic CD8- dendritic cells and marginal
zone B cells by Notch ligands. Int Immunol 21:295–301
Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S et al (2012)
Differential regulation of osteoclastogenesis by Notch2/Delta-like
1 and Notch1/Jagged1 axes. Arthritis Res Ther 14:R45
Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan
GW (2001) Identiﬁcation of novel molecules and pathogenic
pathways in primary biliary cirrhosis: cDNA array analysis of
intrahepatic differential gene expression. Gut 49:565–576
Skokos D, Nussenzweig MC (2007) CD8- DCs induce IL-12-
independent Th1 differentiation through Delta 4 Notch-like ligand
in response to bacterial LPS. J Exp Med 204:1525–1531
Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S et al (2010)
Genome-wide association study meta-analysis identiﬁes seven
new rheumatoid arthritis risk loci. Nat Genet 42:508–514
Swarnkar G, Karuppaiah K, Mbalaviele G, Chen TH, Abu-Amer Y
(2015) Osteopetrosis in TAK1-deﬁcient mice owing to defective
NF-kappaB and NOTCH signaling. Proc Natl Acad Sci USA
112:154–159
Tanigaki K, Honjo T (2007) Regulation of lymphocyte development
by Notch signaling. Nat Immunol 8:451–456
Tan-Pertel HT, Walker L, Browning D, Miyamoto A, Weinmaster G
et al (2000) Notch signaling enhances survival and alters
differentiation of 32D myeloblasts. J Immunol 165:4428–4436
Tsao PN, Wei SC, Huang MT, Lee MC, Chou HC et al (2011)
Lipopolysaccharide-induced Notch signaling activation through
JNK-dependent pathway regulates inﬂammatory response.
J Biomed Sci 18:56
Varnum-Finney B, Purton LE, Yu M, Brashem-Stein C, Flowers D
et al (1998) The Notch ligand, Jagged-1, inﬂuences the devel-
opment of primitive hematopoietic precursor cells. Blood
91:4084–4091
Varnum-Finney B, Brashem-Stein C, Bernstein ID (2003) Combined
effects of Notch signaling and cytokines induce a multiple log
increase in precursors with lymphoid and myeloid reconstituting
ability. Blood 101:1784–1789
Wang YC, Hu XB, He F, Feng F, Wang L et al (2009) Lipopolysac-
charide-induced maturation of bone marrow-derived dendritic
cells is regulated by notch signaling through the up-regulation of
CXCR4. J Biol Chem 284:15993–16003
Wang YC, He F, Feng F, Liu XW, Dong GY et al (2010) Notch
signaling determines the M1 versus M2 polarization of macro-
phages in antitumor immune responses. Cancer Res 70:4840–
4849
Wang H, Zou J, Zhao B, Johannsen E, Ashworth T et al (2011)
Genome-wide analysis reveals conserved and divergent fea-
tures of Notch1/RBPJ binding in human and murine T-lym-
phoblastic leukemia cells. Proc Natl Acad Sci USA 108:14908–
14913
Weber S, Niessen MT, Prox J, Lullmann-Rauch R, Schmitz A et al
(2010) The disintegrin/metalloproteinase Adam10 is essential for
epidermal integrity and Notch-mediated signaling. Development
138:495–505
Weijzen S, Velders MP, Elmishad AG, Bacon PE, Panella JR et al
(2002) The Notch ligand Jagged-1 is able to induce maturation of
monocyte-derived human dendritic cells. J Immunol 169:4273–
4278
Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP et al (2010)
Therapeutic antibody targeting of individual Notch receptors.
Nature 464:1052–1057
Xu H, Zhu J, Smith S, Foldi J, Zhao B et al (2012) Notch-RBP-J
signaling regulates the transcription factor IRF8 to promote
inﬂammatory macrophage polarization. Nat Immunol 13:642–
650
Xu J, Chi F, Guo T, Punj V, Lee WN et al (2015) NOTCH reprograms
mitochondrial metabolism for proinﬂammatory macrophage acti-
vation. J Clin Invest 125:1579–1590
Yabe Y, Matsumoto T, Tsurumoto T, Shindo H (2005) Immunohis-
tological localization of Notch receptors and their ligands Delta
and Jagged in synovial tissues of rheumatoid arthritis. J Orthop
Sci 10:589–594
Yamada T, Yamazaki H, Yamane T, Yoshino M, Okuyama H et al
(2003) Regulation of osteoclast development by Notch signaling
directed to osteoclast precursors and through stromal cells. Blood
101:2227–2234
Yashiro-Ohtani Y, Ohtani T, Pear WS (2010) Notch regulation of
early thymocyte development. Semin Immunol 22:261–269
Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ (2010)
Functions of notch signaling in the immune system: consensus
and controversies. Annu Rev Immunol 28:343–365
Zanotti S, Canalis E (2010) Notch and the skeleton. Mol Cell Biol
30:886–896
Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J et al (2005) Crosstalk
between tumor and endothelial cells promotes tumor angiogen-
esis by MAPK activation of Notch signaling. Cancer Cell 8:13–23
Notch signaling in inﬂammatory responses REVIEW









Zhang W, Xu W, Xiong S (2010) Blockade of Notch1 signaling
alleviates murine lupus via blunting macrophage activation and
M2b polarization. J Immunol 184:6465–6478
Zhang Q, Wang C, Liu Z, Liu X, Han C, et al., (2012) Notch signal
suppresses TLR-triggered inﬂammatory responses in macro-
phages by inhibiting ERK1/2-mediated NF-kappaB activation.
J Biol Chem 287:6208–6217
Zhao B, Ivashkiv LB (2011) Negative regulation of osteoclastoge-
nesis and bone resorption by cytokines and transcriptional
repressors. Arthritis Res Ther 13:234
Zhao B, Zou J, Wang H, Johannsen E, Peng CW et al (2011)
Epstein-Barr virus exploits intrinsic B-lymphocyte transcription
programs to achieve immortal cell growth. Proc Natl Acad Sci
USA 108:14902–14907
Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB (2012) TNF-induced
osteoclastogenesis and inﬂammatory bone resorption are inhib-
ited by transcription factor RBP-J. J Exp Med 209:319–334
Zhou J, Cheng P, Youn JI, Cotter MJ, Gabrilovich DI (2009) Notch
and wingless signaling cooperate in regulation of dendritic cell
differentiation. Immunity 30:845–859
REVIEW Yingli Shang et al.
174 © The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn
P
ro
te
in
&
C
e
ll
